Engineered immune cells take aim at brain tumors
NCT ID NCT07656103
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new cell therapy called QH101 for people with solid tumors that have spread to the brain, spinal cord, or surrounding membranes. The therapy uses specially engineered immune cells designed to better recognize and attack cancer cells. The main goals are to check safety, find the right dose, and see if it can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QH101 cell injection (engineered immune cells)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat brain or spinal cord metastases.
What could go wrong
This is a very early, small study (7 people) testing safety and dosing. The therapy may not work or could cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••